register

News & Trends - Pharmaceuticals

Australian researchers lead world in trial of novel melanoma treatment

Health Industry Hub | June 7, 2021 |
[Total: 1    Average: 5/5]

Pharma News: In a breakthrough which could extend to the treatment of other cancers, a new immune checkpoint inhibitor has proven effective in helping save the lives of advanced melanoma patients.

Bristol-Myers Squibb’s relatlimab is the first immunotherapy treatment to target LAG-3, a protein in immune cells which reinvigorates and enhances the tumour fighting response.

Immune checkpoint inhibitors targeting the CTLA-4 and PD-1 proteins have revolutionised treatment of advanced melanoma over the past seven years. These treatments are most effective when used in combination, but this tends to increase their toxicity. Some 50% of patients either do not respond, or develop resistance to these treatments and therefore it is vital that new treatments are developed.

Melanoma Institute Australia (MIA) Co-Medical Director, Professor Georgina Long AO of The University of Sydney, said the successful trial of relatlimab, targeting the LAG-3 protein, makes it a critical new weapon in the fight to save all lives from melanoma.

“This drug gives us a third immune checkpoint inhibitor to add to the treatment toolkit which may be the difference between survival or not for melanoma patients around the world.

“Australian researchers and patients were critical to trialling this new treatment which has very real potential to also extend to other cancers,” Professor Long said.

The findings from the RELATIVITY-047 trial will be presented at the American Society of Clinical Oncology (ASCO) congress 2021. Professor Georgina Long is the senior lead author for the international trial and MIA was a leading contributor of patients for the study.

Results showed that in previously untreated advanced melanoma patients, combining relatlimab with BMS’s Opdivo (nivolumab – immune checkpoint inhibitor targeting the PD-1 protein) doubled the progression free survival time compared to the use of nivolumab alone (10.1 vs 4.6 months respectively).

At one year, almost 50% of patients on the combination therapy had no disease progression, whereas nearly two-thirds of patients on the single therapy had progressed. Importantly, the combined therapy was also far less toxic to patients.

“Immunotherapy has already transformed the treatment of melanoma and other cancers, with anti-PD-1 therapies leading the way,” Professor Long said.

“This new immune checkpoint inhibitor that targets LAG-3, and its proven effectiveness when used in combination, improves outcomes for melanoma patients even further and will likely impact cancer treatment globally,” she noted.


News & Trends - Medical Technology

MedTech News - ASO warns against US-style managed care as ACCC looks into buying group

ASO warns against US-style managed care as ACCC considers authorising buying group

Health Industry Hub | June 21, 2021 |

MedTech News: The private health insurers lobby regularly with the Federal Government claiming a crisis of affordability in private health […]

More


Digital & Innovation

Healthcare Technology Digital Innovations -

Roche joins ANDHealth to drive growth of digital health sector

Health Industry Hub | June 21, 2021 |

Digital & Innovation: Australia’s decades-long policy of supporting innovation, significant investment into digital health infrastructure, and successful management of the […]

More


Digital & Innovation

Baxter launches digital resource for patients with chronic kidney disease

Health Industry Hub | June 21, 2021 |

MedTech News: Baxter Healthcare (Baxter), a global leader in dialysis care, announced today the launch of a new online portal […]

More


Digital & Innovation

Healthcare Technology Digital Innovations - Australian consumers to play key role in reimagining virtual health technologies

Australian consumers to play key role in reimagining virtual health technologies

Health Industry Hub | June 21, 2021 |

Digital & Innovation: A first of its kind national survey has been launched to Australian consumers this week, garnering insights […]

More